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 
Abstract— Platelets are blood components with high 
biomedical potential due to their physiological role in wound 
healing and their rich growth factor content. This paper 
describes proof of concept experiments aimed to produce a new 
blood derived product by applying Pulsed Electric Fields (PEF) 
in platelet concentrates with no therapeutic value for transfusion 
medicine. A human platelet concentrate suspension was 
subjected to a PEF treatment of 1 pulse, 5 kV/cm, with 2 μs. 
Release of Platelet Derived Growth Factor (PDGF) from the 
electroporated platelets was measured by ELISA. Furthermore, 
the biological activity of the obtained blood derived product was 
characterized. Human mesenchymal stem cells (hMSC) were 
cultured in the presence of the proteins released from the 
platelets after PEF application and evaluated for their expansion 
potential. 
Results show that platelets concentrates submitted to a single 
PEF treatment can release PDGF to the supernatant. Protein 
release from the single and transient PEF cycle was confirmed 
by the expansion of hMSC cultured with a medium 
supplemented with platelet releasate obtained from 
electroporated platelets. These results support the valorization 
of platelet concentrates with no transfusion value that would 
otherwise be discarded. Applying PEF might allow the 
development of alternative releasate for different biomedical 
applications, namely stem cells culture. 
I. INTRODUCTION 
Platelets constitute a vital component of blood, primarily 
responsible for bleeding cessation. Standard blood bank 
procedures are designed to keep Platelet Concentrates (PC) 
viable and functional by strict room temperature storage 
requirements and continuous agitation. Nevertheless, PC only 
have a 5-day shelf-life (or 7-day if submitted to pathogen 
reduction), and when stored at 20-24ºC with continuous 
agitation [26, 27].  Expired platelets are no longer suitable for 
transfusion, but they still have the potential for alternative 
biomedical applications. Converting these PC, with no 
transfusional value, into new biological blood-derivative 
product with high biomedical potential is one possibility for 
blood banks diversification in terms of Cellular Therapies and 
Regenerative Medicine.  
Platelets are also known for their enriched content in 
bioactive factors. Fundamental in vitro studies have been 
carried out over the years to understand the mechanisms of 
growth-promoting and tissue-healing capacity of platelet-
derived factors [1, 2, 3]. When activated in our body, platelets 
release a group of bioactive molecules that promote the 
recruitment, growth, and morphogenesis of cells, wound 
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healing and tissue regeneration [4-5]. Some of the factors 
found inside the platelets comprise isoforms of PDGF, Insulin 
Growth Factor (IGF), Transforming Growth Factor (TGF), 
known to contribute for stem cell expansion and differentiation 
into different lineages such as osteoblasts [6, 7]. In fact, PC 
can be used as an alternative source of growth factors for 
therapeutic applications and constitute a very exciting area of 
research. In the past two decades, the increasing knowledge on 
the physiological role of platelets in wound healing and tissue 
injury suggests the potential of using activated platelets as 
topical therapeutic tool [8].  
Considerable effort has been done to evaluate the role of 
Platelet Lysate (PL), obtained after activation of platelets and 
consequent release of their intracellular protein content, as a 
supplement for in vitro cell culture. PL has shown to accelerate 
cell expansion in vitro, thus reducing the duration of ex vivo 
manipulation [9-11] and proving its capacity to replace fetal 
bovine serum (FBS), the conventional animal source 
supplement. 
Platelet activation can be initiated by several methods, 
such as shear forces, or contact with collagen and thrombin 
[12]. Calcium also activates platelets as it replaces the calcium 
bound by the anticoagulant agents, used to avoid coagulation 
of the collected whole blood [13]. Exogenous thrombin can 
also be provided; nevertheless the use of animal-derived 
thrombin has raised concerns regarding safety of the final 
product [1]. Studies also show that using thrombin fails to 
maximize the potential of PL [2]. Freeze and thaw cycles are 
also used for activation of these blood components. The rate 
of activation is quite successful as these temperature cycles 
induce lysis of the cells [6]. However, this method leads to 
irreversible activation of platelets, with poor control over the 
final obtained product. Therefore, other activation stimuli are 
required to overcome these limitations.   
The application of pulsed electric fields (PEF) in biological 
cell systems is a known technique to induce cell membrane 
permeabilization, called electroporation [14-20]. This 
technology is already being proposed to enable endogenous 
proteins to be released in platelets [21-24]; however no studies 
have demonstrated the ability to define a specific pulse to 
achieve certain final protein content.  
In this study, a proof-of-concept for the valorization of PC 
with no transfusion value is presented. The goal is to propose 
a new methodology for producing a new blood-derived 
product for non-transfusion applications, with high therapeutic 
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and commercial value, where the high potential of PEF 
technology is expected to contribute for this methodology. In 
this first study, a platelet concentrate with no transfusion value 
was subjected to a PEF treatment consisting of one 5 kV/cm 
pulse with 2μs and the release of PDGF was measured by 
ELISA. Furthermore, the biological activity of the obtained 
platelet releasate was characterized. hMSC were cultured in 
the presence of medium supplemented with platelet releasate 
after electroporation with PEF and evaluated for their 
expansion and differentiation potential. 
II. METHODS 
A. Human Platelet Concentrates (PC) 
PC were made available by the Portuguese Institute for 
Blood and Transplantation (IPST, Lisbon, Portugal) from 
material not suitable for transfusion. PC follow a well-defined 
composition of more than 2 x 1011 platelets per unit (11350 
mL); less than 1 x 106 white blood cells and less than 3 x 109 
red blood cells. For this study, PC were kept in agitation and 
20-24°C between 6 and 10 days. 
B. Freeze &Thaw cycles 
Part of the collected samples were subjected to three 
repeated temperature cycles: samples were frozen with liquid 
nitrogen at -196 ºC and thawed at 37 ºC in a sterile water bath). 
After the temperature cycles, samples were stored at -20 ºC 
until further use. Before storing at -20 °C, samples were 
centrifuged (1400 xg, 10 min) to remove remaining platelets 
and platelet debris. These samples were called PL F&T (PC 
lysate by freeze & thaw cycles). 
C. PEF application 
EPULSUS®-LPM1-10 (EnergyPulse Systems, Lisbon, 
Portugal) PEF generator was used to apply the PEF protocol. 
Pulse voltage and current were recorded with a Tektronix 
TPS2024B 200MHz 2GS/s oscilloscope, using PMK 
PHV1000 100:1 400MHz 50MΩ//7.5pF high voltage probe 
and current transformer model 0.5-0.01 (Stangenes Industries 
Inc, Palo Alto, CA). PEF treatments were applied to a parallel 
plate titanium electrodes treatment chamber with 1 cm gap and 
a surface area of 1 cm2. Batches of 1 mL were treated with 1 
pulse of 2 μs at 5 kV/cm. Other protocols, with higher electric 
fields, were tested unsuccessfully due to breakdown problems 
on the surface of the treated volume, due to the design of the 
treatment chamber.  
After PEF application, PC was removed from treatment 
chamber and centrifuged in 1.5 mL Eppendorf tube (1400 xg, 
10 min) to remove debris and remaining platelets. . Resulting 
supernatant (releasate) was stored at -20 ˚C until further 
analysis. These samples were called PR PEF (PC releasate 
treated with PEF). 
PC samples were also processed without PEF (PR wo act). 
These samples were used to isolate the effect of PEF from the 
rest of the process (centrifugation, age of culture, others). 
D. Growth Factor Quantification 
PDGF release was measured using ELISA kits (Human 
PDGF-BB Quantikine ELISA Kit, bio-techne/R&D Systems, 
Minneapolis, MN, USA) to determine the concentration of 
PDGF in the samples. The protocol was followed according to 
kit instructions. Optical density was read at 450 nm (n=3) 
using a multi-well plate reader (Tecan). 
A. hMCS Culture 
The releasate obtained from PEF exposure was tested for 
biocompatibility and bioactivity using hMSC isolated from the 
bone marrow (donor 00055; RoosterBio, Maryland, USA). 
Five different conditions were used to compare the 
bioactivity of the PEF releasate: 
a. Control 1 – cells cultured in MesencultTM-XF on a 
surface coated with  MesencultTM- Attachment substrate 
(both from STEMCELLTMTechnologies, Vancouver, 
Canada) – optimized medium formulation for hMSC 
expansion; 
b. Control 2 – cells cultured in DMEM-LG + 10% FBS 
(ThermoFisherTMScientific, Massachusetts, USA), – animal 
source, commercially alternative to human platelets 
derivatives; 
c. PR wo act – cells cultured in DMEM-LG + 10% PR 
without activation; 
d. PL F&T – cells cultured in DMEM-LG + 10% PL 
submitted to freeze/thaw cycles ; 
e. PR PEF – cells cultured in DMEM-LG + 10% PR 
treated by PEF.  
In all conditions, the medium was supplemented with 2 
mM of glutamine (Life Technologies, USA). 
hMSCs were inoculated at a density of 4500 cell/cm2 in 
adherent static culture systems (12- and 48- well plates), and 
cultured for 7 days at 37 °C in a humidified atmosphere of 5% 
CO2 and 95% air. 
Medium was changed at day 4. Cultures were monitored in 
terms of:  
a. Cell adhesion efficiency – 24 h after inoculation; by 
counting the cells in a hemocytometer using trypan blue 
exclusion test. Cell adhesion efficiency was estimated by 
calculating the ratio between the number of cells attained 24h 
after inoculation with the initial cell number at the inoculum.  
b. Cell growth – cell concentration was determined at day 
1, 4 and 7 by counting the cells in a hemocytometer using 
trypan blue exclusion test. Cell expansion factor was estimated 
by calculating the ratio between the number of cells attained at 
day 7 with the cell number estimated at day 1; 
c. Cell morphology - day 1, day 4 and day 7; by phase 
contrast microscopy; 
Methods used for cell culture and characterization were 
performed according to previous publication [25]. All tests 
were performed in duplicates. 
III. RESULTS AND DISCUSSION 
A.  PDGF quantification 
The release of PDGF from the platelets was quantified by 
ELISA and results are presented in Fig 1. PR wo act show the 
lowest value (8.59 ± 0.05 μg/mL) followed by PR PEF with 
9.08 ± 0.10 μg/mL and PL F&T with 12.78 ± 0.32 μg/mL. 
Against PR wo act, PR PEF has an increase of 6% on PDGF 
concentration and PL F&T has an increase of 48% on PDGF 
concentration. Although, is only a small difference between 
PR wo act and PR PEF, standard deviation of the analyses 
points to a significant difference between the two values and 
  
were interpreted here as a difference promoted by the exposure 
to PEF. However, against PDGF value obtained with F&T 
treatment (PL F&T), one conclude that the release (PR PEF) 
is only partial, since the values are still considerably lower. 
The difference in PDGF concentration measured suggests that 
only part of the platelets population is being affected by the 
PEF treatment. Another hypothesis is that PEF can only 
promote a partial release of the components. Only with the 
available results of this work it is not possible to conclude on 
this subject and further optimization of the PEF protocol is 
necessary. 
Nevertheless, the tested PEF protocol shows it is possible 
to promote release of components using only pulsed electric 
fields as an alternative to thrombin or Ca2+ described by [22]. 
We also believe that this proof-of-concept study shows that 
there is potential to develop more elegant releasate methods 
that trigger selective release of platelets without inducing 
complete disruption of cell membrane. 
B. hMSC culture 
Cell adhesion efficiency - After the first day of culture, it is 
possible to see that cell adhesion efficiency was high in all 
cultures supplemented with PL and PR (Fig. 2). The values 
obtained for the three conditions were very similar between 
them and to cells cultured in MesencultTM-XF (Control 1). 
This observation demonstrates that, in general, growth factors 
and other molecules kept their biological activity after PEF 
treatment, because (PR PEF)-supplemented cultures showed 
proportional growth in relation to PL F&T and PR wo act. This 
observation is important as a start point to understand that 
electric field applied is not changing the structure of the 
proteins (such as PDGF and other growth factors). The lowest 
percentage of adherent cells was attained for cultures with 
DMEM-LG supplemented with 10% FBS (Control 2). 
Cell growth – From Fig. 3 and Fig. 4 it is possible to observe 
that cell proliferation was higher in all PL and PR 
supplemented medium conditions than in FBS supplemented 
medium. Furthermore, both PL F&T and PR PEF samples 
show higher concentration levels than cells supplemented with 
PR wo act. This supports the idea that the composition of PR 
PEF is more similar to PL F&T than PR wo act and that this 
composition is beneficial for hMSC growth. This observation 
is also in accordance with the PDGF quantification results, 
where a small increase of 6% on the PDGF concentration 
expresses a small increase on the cell growth on the hMSC 
cultures. Only the cells that were cultured with PL F&T 
showed an expansion factor similar to Control 1. These results 
supports the idea that it is possible to present a natural, human 
origin, culture medium with a performance similar to the 
synthetic optimized MesencultTM-XF, needed for biomedical 
applications. 
 
Cell Morphology – hMSC show different morphologies in 
the different culture conditions evaluated. In particular, cells 
display a star-shaped with accentuated membrane regions 
when cultured in PL and PR supplemented media. In Control 
1 cells showed an elongated, fibroblastic-like, spindle-shaped 
morphology whereas in Control 2 some flattened and star-like 
shape cells with prominent nucleus were observed. This 
observation supports the importance of creating products that 
are human derived, not only for ethical reasons but also to 
improve the quality of all products produced downstream. 
 
 
Figure 2. PDGF concentration (μg/mL) for different processing 
conditions. 
 
Figure 1. Cell density (cell/cm2) for all tested conditions. 
 
Figure 3. Cell Expansion Factor after 7 days for all tested conditions. 
 
Figure 4. Cell adhesion efficiency for different supplemented 
conditions of hMSC cultures. 
  
IV. CONCLUSION 
In conclusion, this work demonstrates the potential of PEF 
for the transformation of a PC with no transfusional 
application into a new and valuable product for biomedical 
applications (platelet releasate). However, further work must 
be done, in order to optimize PEF application and making it a 
real alternative technology for industrial scale production of 
such products. Next steps should focus on optimizing the PEF 
protocol and treatment chamber design in order to increase the 
release of intracellular components from the platelets. 
PEF protocol should also be used in an attempt to 
selectively activate platelets to extract specific molecules. For 
this, more studies should be done focusing on specific growth 
factors or other molecules of interest for biomedical and 
biotechnology applications. 
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